An interpretable machine learning model based on a quick pre-screening system enables accurate deterioration risk prediction for COVID-19.

Journal: Scientific reports
Published Date:

Abstract

A high-performing interpretable model is proposed to predict the risk of deterioration in coronavirus disease 2019 (COVID-19) patients. The model was developed using a cohort of 3028 patients diagnosed with COVID-19 and exhibiting common clinical symptoms that were internally verified (AUC 0.8517, 95% CI 0.8433, 0.8601). A total of 15 high risk factors for deterioration and their approximate warning ranges were identified. This included prothrombin time (PT), prothrombin activity, lactate dehydrogenase, international normalized ratio, heart rate, body-mass index (BMI), D-dimer, creatine kinase, hematocrit, urine specific gravity, magnesium, globulin, activated partial thromboplastin time, lymphocyte count (L%), and platelet count. Four of these indicators (PT, heart rate, BMI, HCT) and comorbidities were selected for a streamlined combination of indicators to produce faster results. The resulting model showed good predictive performance (AUC 0.7941 95% CI 0.7926, 0.8151). A website for quick pre-screening online was also developed as part of the study.

Authors

  • Lijing Jia
    Department of Emergency, The First Medical Center to Chinese People's Liberation Army General Hospital, Beijing, China.
  • Zijian Wei
    Washington University in St. Louis, St. Louis, USA.
  • Heng Zhang
    Department of Gastroenterology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Jiaming Wang
    Institute of Biophysics, Chinese Academy of Science, Beijing 100101, China.
  • Ruiqi Jia
    School of Economics and Management, Beijing Jiaotong University, Beijing, China.
  • Manhong Zhou
    Department of Emergency, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
  • Xueyan Li
    College of Electronic Science and Engineering, Jilin University, Changchun, China. Electronic address: leexy@jlu.edu.cn.
  • Hankun Zhang
    School of E-Business and Logistics, Beijing Technology and Business University, Beijing, China.
  • Xuedong Chen
    School of Economics and Management, Beijing Jiaotong University, Beijing, China.
  • Zheyuan Yu
    School of Economics and Management, Beijing Jiaotong University, Beijing, China.
  • Zhaohong Wang
    School of Economics and Management, Beijing Jiaotong University, Beijing, China.
  • Xiucheng Li
    School of Economics and Management, Beijing Jiaotong University, Beijing, China.
  • Tingting Li
    Key Laboratory of Biotechnology and Bioresources Utilization (Dalian Minzu University), Ministry of Education, Dalian, China.
  • Xiangge Liu
    School of Economics and Management, Beijing Jiaotong University, Beijing, China.
  • Pei Liu
    School of Life Sciences, Nanjing University, State Key Laboratory of Pharmaceutical Biotechnology, Nanjing 210000, China.
  • Wei Chen
    Department of Urology, Zigong Fourth People's Hospital, Sichuan, China.
  • Jing Li
    Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin, China.
  • Kunlun He
    Beijing Key Laboratory of Precision Medicine for Chronic Heart Failure, Chinese PLA General Hospital, Beijing, China.